D-0511-2025 Class II Ongoing

Recalled by Breckenridge Pharmaceutical, Inc. — Berkeley Heights, NJ

Recall Details

Product Type
Drugs
Report Date
July 16, 2025
Initiation Date
June 30, 2025
Termination Date
N/A
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
12,242 30-count bottles

Product Description

Duloxetine Delayed-Release Capsules, USP, 40mg, 30-count bottles, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-750-33.

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Distribution Pattern

U.S. Nationwide

Code Information

Lot # 230199, Exp. Date 01/31/2026